The U.S. Food and Drug Administration (FDA) this week approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe type I leukocyte adhesion deficiency (LAD-I). The autologous hematopoietic stem cell gene therapy addresses the underlying genetic cause of this ultra-rare, life-threatening pediatric immunodeficiency, offering a potentially curative alternative to high-risk allogeneic stem cell transplantation.
Regulatory Milestone
Item
Detail
Agency
U.S. Food and Drug Administration (FDA)
Approval Type
First gene therapy for LAD-I
Product
Kresladi (marnetegragene autotemcel)
Developer
Rocket Pharmaceuticals (local U.S. firm)
Indication
Severe leukocyte adhesion deficiency type I (LAD-I)
Approval Significance
First and only approved therapy for severe LAD-I
Disease Context & Unmet Need
Parameter
Severe LAD-I Profile
Genetic Basis
Autosomal recessive mutations in ITGB2 gene
Pathophysiology
Defective CD18/CD11a integrin expression – white blood cells unable to migrate to infection sites
In-house lentiviral vector and cell processing capabilities; capacity for 20–30 patients annually initially
Competitive Landscape
First-mover advantage – no other LAD-I gene therapies in clinical development
Commercial Strategy:Center of Excellence model – treatment at specialized pediatric immunology/transplant centers; patient identification via newborn screening expansion advocacy
Global Expansion: EMA filing 2026–2027; Japan PMDA pathway for rare pediatric diseases
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch execution, manufacturing scale-up, and global regulatory expansion for Kresladi. Actual results may differ due to reimbursement negotiations for ultra-high-cost gene therapies, long-term durability data requirements, and competitive entry from allogeneic “off-the-shelf” cell therapy approaches.-Fineline Info & Tech
By Fineline Cube